Logo

Genetic Technologies Settles Patent Dispute with Bioscientia Institute

Jun 24, 2013 | staff reporter

NEW YORK (GenomeWeb News) – Genetic Technologies today announced it has settled a legal dispute with Bioscientia Institute for Medical Diagnostics and will withdraw its lawsuit against the German firm.

Melbourne, Australia-based GTG initiated legal action against Bioscientia in March related to GTG's non-coding technology. The company did not disclose details about the lawsuit, but GTG has sued numerous companies, alleging infringement of US Patent No. 5,612,179.

It has settled with several firms over its allegations, and today's announcement follows similar settlements announced in April with the Genetics & IVF Institute and PreventionGenetics.

Financial and other terms of today's deal were not disclosed.

Filed under

Diagnostics
Cancer
Business News
Tools & Technology
intellectual property
Breast Cancer
non-coding DNA
Genetic Technologies
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.